ImmunityBio Files 8-K: Material Agreement and Financial Updates
Ticker: IBRX · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2026 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $75.0 million, $375.0 million, $25.0 million, $480.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, regulation-fd
Related Tickers: IBIO
TL;DR
IBIO inked a new deal, expect financial updates soon.
AI Summary
On March 30, 2026, ImmunityBio, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also made a Regulation FD disclosure and reported other events, along with filing financial statements and exhibits.
Why It Matters
This filing indicates a significant new agreement and potential financial obligations for ImmunityBio, Inc., which could impact its future operations and financial health.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and financial obligations, which inherently carry risk and require further investigation into the specifics.
Key Players & Entities
- ImmunityBio, Inc. (company) — Filer of the 8-K report
- 0001326110 (company) — CIK number for ImmunityBio, Inc.
- 2026-03-30 (date) — Period of report for the 8-K filing
- 2026-03-31 (date) — Filing date and acceptance date of the 8-K report
FAQ
What is the nature of the material definitive agreement entered into by ImmunityBio, Inc. on March 30, 2026?
The filing indicates Item 1.01 covers the 'Entry into a Material Definitive Agreement', but the specific details of the agreement are not provided in this summary.
What type of direct financial obligation was created for ImmunityBio, Inc.?
Item 2.03 of the filing addresses the 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant', but the specifics of the obligation are not detailed here.
What information was disclosed under Regulation FD?
Item 7.01 of the filing pertains to 'Regulation FD Disclosure', suggesting that material information was disseminated to the public.
Are there any other significant events reported in this 8-K filing?
Yes, Item 8.01 is designated for 'Other Events', indicating that additional material events beyond the agreement and financial obligations are being reported.
What financial statements and exhibits are included with this filing?
Item 9.01 of the filing covers 'Financial Statements and Exhibits', and the document list shows EX-10.1, EX-99.1, and other related files.
Filing Stats: 1,314 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2026-03-31 08:24:54
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Se
- $75.0 million — e Company for a gross purchase price of $75.0 million (the "Third Payment") paid at the closi
- $375.0 million — 2029 (the "Test Date") equal or exceed $375.0 million (the "Cumulative Purchaser Payments") a
- $25.0 million — ientific and Medical Officer, converted $25.0 million of the principal amount outstanding und
- $480.0 million — nder the Convertible Promissory Note is $480.0 million. Item9.01 Financial Statements and E
Filing Documents
- d139829d8k.htm (8-K) — 35KB
- d139829dex101.htm (EX-10.1) — 695KB
- d139829dex991.htm (EX-99.1) — 19KB
- g139829dsp00132.jpg (GRAPHIC) — 6KB
- 0001193125-26-133363.txt ( ) — 1039KB
- ibrx-20260330.xsd (EX-101.SCH) — 3KB
- ibrx-20260330_lab.xml (EX-101.LAB) — 17KB
- ibrx-20260330_pre.xml (EX-101.PRE) — 11KB
- d139829d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 10.1* Second Amendment to Revenue Interest Purchase Agreement, dated as of March 30, 2026 by and among the Company, guarantors party thereto, the purchasers party thereto, and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers. 99.1** Press Release dated March 31, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Filed herewith. ** Furnished herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: March 31, 2026 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer